{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:15:54Z","timestamp":1788444954684,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>EGFR<\/jats:italic>\n                    exon 20 insertion (ex20ins) NSCLC typically shows limited response to immunotherapy. We report a rare case of a smoker with metastatic\n                    <jats:italic>EGFR<\/jats:italic>\n                    ex20ins (p.S768_D770dup) and high PD-L1 expression (TPS 50%) who achieved exceptional survival (OS\u00a0=\u00a063 months). Following progression on chemotherapy and intolerance to afatinib, the patient received paclitaxel plus tislelizumab. This combination yielded durable disease control. While the overall benefit of immune checkpoint inhibitors (ICIs) in EGFR-mutant NSCLC remains limited, this case suggests that chemo-immunotherapy (particularly taxane + PD-1 inhibition) may provide significant benefit in ex20ins tumors with high PD-L1 expression and smoking history. These findings highlight the critical value of targeted molecular profiling and offer a viable precision oncology strategy when novel targeted agents are inaccessible.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1892764","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:43Z","timestamp":1784699563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Exceptional survival with immunotherapy in a patient with EGFR exon 20 insertion (p.S768_D770dup) and high PD-L1 expression"],"prefix":"10.3389","volume":"17","author":[{"given":"Shasha","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Oncology, Xingyi People\u2019s Hospital","place":["Xingyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xingyi People\u2019s Hospital","place":["Xingyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xingyi People\u2019s Hospital","place":["Xingyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xingyi People\u2019s Hospital","place":["Xingyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.030","article-title":"Lazertinib versus osimertinib in previously untreated EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA","volume":"20","author":"Lee","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2417144121","article-title":"Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity","volume":"121","author":"Zhao","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3727\/096504022x16462176651719","article-title":"Research progress in immunotherapy of NSCLC with EGFR-sensitive mutations","volume":"29","author":"Yang","year":"2022","journal-title":"Oncol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.11.020","article-title":"Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"s964","DOI":"10.1016\/j.annonc.2021.08.1815","article-title":"Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)","volume":"32","author":"Han","year":"2021","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006887","article-title":"Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy","volume":"11","author":"Zhong","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161718","article-title":"Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1\u226550% who developed EGFR-TKI resistance","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671228","article-title":"Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-mutant NSCLC","volume":"11","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.21037\/tlcr-23-167","article-title":"Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100253","article-title":"The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma","volume":"6","author":"Kirchner","year":"2021","journal-title":"ESMO Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.9052","article-title":"Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint inhibitors in non-small cell lung cancer","volume":"36","author":"Negrao","year":"2018","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/genes12050679","article-title":"Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations","volume":"12","author":"Metro","year":"2021","journal-title":"Genes (Basel)"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1952941","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1892764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:40:38Z","timestamp":1788442838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1892764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1892764"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1892764","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1892764"}}